The Europe endothelial dysfunction market is expected to grow from US$ 611.28 million in 2022 to US$ 776.37 million by 2028. It is estimated to grow at a CAGR of 4.1% from 2022 to 2028.
Hypertension is the leading cause of cardiovascular disease and premature death worldwide. The number of adults aged 30-79 with hypertension has increased from 650 million to 1.28 billion over the past 30 years, according to the first comprehensive global analysis of trends in the prevalence, detection, treatment, and control of hypertension among the population, headed by Imperial College London and WHO.
Based on cause, the Europe endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest Europe endothelial dysfunction market share in 2022.
Based on test type, the Europe endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger Europe endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the Europe endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest Europe endothelial dysfunction market share in 2022.
Based on country, the Europe endothelial dysfunction market is segmented into the UK, Germany, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe endothelial dysfunction market in 2022.
ZOLL Medical Corp, Sphingo Tec GmbH, The Polymath Co, SMART Medical Ltd, Alam Medical SaRl, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.
Rising Incidences of High Cholesterol, Diabetes and Obesity Fuels Europe Endothelial Dysfunction Market
Lifestyle changes lead to a rise in the incidences of diabetes, hypertension, dyslipidemia, and obesity, increasing the chances of endothelial dysfunction. However, these can be prevented through proactive monitoring, early diagnosis, and physical activity. Metabolic syndrome is a group of disorders that increases the risk of CAD, diabetes, high blood pressure, and other serious health problems. Type 2 diabetes is already a major public health problem and is increasingly rising among the children and young adults associated with obesity. According to the World Health Organization (WHO), diabetes was the direct cause of 1.5 million deaths in 2019, and 48% of all deaths from diabetes occurred before age 70. Another 460,000 deaths from kidney disease were caused by diabetes. Elevated blood sugar causes ~20% of cardiovascular deaths.Hypertension is the leading cause of cardiovascular disease and premature death worldwide. The number of adults aged 30-79 with hypertension has increased from 650 million to 1.28 billion over the past 30 years, according to the first comprehensive global analysis of trends in the prevalence, detection, treatment, and control of hypertension among the population, headed by Imperial College London and WHO.
Europe Endothelial Dysfunction Market Overview
The endothelial dysfunction market in Europe is sub-segmented into the UK, Germany, Italy, France, Spain, and the Rest of Europe. The rising prevalence of cardiovascular diseases, an increase in the aging population, and a growing number of research and development activities are the key factors contributing to the market growth in the region. Further, product launches and government investments would facilitate the market growth during the forecast period.Europe Endothelial Dysfunction Market Revenue and Forecast to 2028 (US$ Million)
Europe Endothelial Dysfunction Market Segmentation
The Europe endothelial dysfunction market is segmented into cause, test type, end user, and country.Based on cause, the Europe endothelial dysfunction market is segmented into hypertension, hypercholesterolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment registered the largest Europe endothelial dysfunction market share in 2022.
Based on test type, the Europe endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held a larger Europe endothelial dysfunction market share in 2022. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the Europe endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held the largest Europe endothelial dysfunction market share in 2022.
Based on country, the Europe endothelial dysfunction market is segmented into the UK, Germany, Italy, France, Spain, and the Rest of Europe. Germany dominated the Europe endothelial dysfunction market in 2022.
ZOLL Medical Corp, Sphingo Tec GmbH, The Polymath Co, SMART Medical Ltd, Alam Medical SaRl, and Medizinische Messtechnik GmbH are some of the leading companies operating in the endothelial dysfunction market in the region.
Table of Contents
1. Introduction
3. Research Methodology
4. Europe Endothelial Dysfunction Market - Market Landscape
5. Europe Endothelial Dysfunction Market - Key Market Dynamics
6. Endothelial Dysfunction Market - Europe Analysis
7. Europe Endothelial Dysfunction Market Analysis - by Cause
8. Europe Endothelial Dysfunction Market Analysis - by Test Type
9. Europe Endothelial Dysfunction Market Analysis - by End User
10. Europe Endothelial Dysfunction Market - Revenue and Forecast to 2028 - Country Analysis
11. Europe Endothelial Dysfunction Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Executive Summary
At 4.1% CAGR, the Europe Endothelial Dysfunction Market is Speculated to be Worth US$ 776.37 million by 2028.According to this research,, the Europe endothelial dysfunction market was valued at US$ 611.28 million in 2022 and is expected to reach US$ 776.37 million by 2028, registering a CAGR of 4.1% from 2022 to 2028. Increasing incidences of cardiovascular diseases and rising incidences of high cholesterol, diabetes and obesity are the critical factors attributed to the Europe endothelial dysfunction market expansion.
Examining endothelial function can improve risk stratification, improve early disease detection, and assess vascular response to therapeutic interventions. There are studies to understand the pathophysiological mechanisms underlying endothelial dysfunction and atherosclerosis progression in a better way and identify new biomarkers and therapeutic strategies to prevent endothelial dysfunction and atherosclerosis to reduce the risk of developing coronary artery disease (CAD) and related complications. Using liquid biopsies and new molecular biology techniques has enabled the identification of a growing list of molecular and cellular markers of endothelial dysfunction that have provided insight into the molecular basis of atherosclerosis as well as potential biomarkers and therapeutic targets for the prevention and treatment of atherosclerosis and CAD.
Research on biomarkers and their clinical application has increased exponentially over the last few decades. Invaluable insight into the pathophysiology of atherosclerosis and the development of novel therapies have been provided by systemic biomarkers. Endothelial dysfunction and inflammation play a central role in the development and progression of CAD. Inflammatory mediators are secreted by inflammatory and vascular cells in atherosclerotic plaque or by organs such as the liver or adipose tissue. Therefore, several inflammation-related factors are considered biomarkers for the early prediction of coronary artery disease. Clinical studies have extensively examined acute phase proteins, cytokines, adhesion molecules, and microparticles as endothelial dysfunction and inflammation markers.
On the contrary, disadvantages associated with the techniques for screening of endothelial dysfunction hurdles the growth of Europe endothelial dysfunction market.
Based on cause, the Europe endothelial dysfunction market is segmented into hypertension, hypercholestrolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment held 32.8% share of Europe endothelial dysfunction market in 2022, amassing US$ 200.71 million. It is projected to garner US$ 262.23 million by 2028 to expand at 4.6% CAGR during 2022-2028.
Based on test type, the Europe endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held 73.9% share of Europe endothelial dysfunction market in 2022, amassing US$ 451.80 million. It is projected to garner US$ 565.80 million by 2028 to expand at 3.8% CAGR during 2022-2028. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.
Based on end user, the Europe endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others. The hospitals segment held 52.1% share of Europe endothelial dysfunction market in 2022, amassing US$ 318.43 million. It is projected to garner US$ 412.44 million by 2028 to expand at 4.4% CAGR during 2022-2028.
Based on country, the Europe endothelial dysfunction market has been categorized into the UK, Germany, Italy, France, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.2% share of Europe endothelial dysfunction market in 2022. It was assessed at US$ 178.57 million in 2022 and is likely to hit US$ 237.54 million by 2028, exhibiting a CAGR of 4.9% during 2022-2028.
Key players operating in the Europe endothelial dysfunction are ZOLL Medical Corp, Sphingo Tec GmbH, The Polymath Co, SMART Medical Ltd, Alam Medical SaRl, and Medizinische Messtechnik GmbH, among others.
In July 2020, SphingoTec launched point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction. The company launched its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).
Companies Mentioned
- Alam Medical SaRl
- Medizinische Messtechnik GmbH
- SMART Medical Ltd
- Sphingo Tec GmbH
- The Polymath Co
- ZOLL Medical Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 122 |
| Published | December 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value in 2022 | 611.28 Million |
| Forecasted Market Value by 2028 | 776.37 Million |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 6 |
